Cargando…
The risk of respiratory tract infections in patients with psoriasis treated with interleukin 23 pathway–inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic
Autores principales: | Syed, Maha N., Shin, Daniel B., Wan, Marilyn T., Winthrop, Kevin L., Gelfand, Joel M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
by the American Academy of Dermatology, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331500/ https://www.ncbi.nlm.nih.gov/pubmed/32622891 http://dx.doi.org/10.1016/j.jaad.2020.06.1014 |
Ejemplares similares
-
The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway–inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic
por: Wan, Marilyn T., et al.
Publicado: (2020) -
Effect of anti–tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in patients with psoriasis—A meta-estimate of pivotal phase 3 trials relevant to decision making during the COVID-19 pandemic
por: Syed, Maha N., et al.
Publicado: (2021) -
Reply to: “Do IL-17 inhibitors increase risk of respiratory tract infections?”
por: Wan, Marilyn T., et al.
Publicado: (2020) -
The Interleukin-23/Interleukin-17 Axis Links Adaptive and Innate Immunity in Psoriasis
por: Schön, Michael P., et al.
Publicado: (2018) -
Pivot Points: Five Decisions Every Successful Leader Must Make
por: Peters, Julia
Publicado: (2014)